Azacitidine In Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Emilie Saucier,Florence Rabian,Hélène Boutroux,Marion Strullu,Karine Morand,Florian Chevillon,Benoit Brethon,Nicolas Boissel,Guy Leverger,André Baruchel

BLOOD（2019）

引用 0|浏览24

暂无评分

摘要

Purpose: Hypomethylating agents are approved in adults with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). By contrast, data in pediatric hematologic malignancies are scarce. Herein, we report the off-label administration of Azacitidine (Aza) in a cohort of children, adolescents and young adults (AYA).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要